Targeting inflammatory pathway reduces Alzheimer's disease in mice

Alzheimer's disease (AD) is the most common form of dementia and is characterized by the formation of β-amyloid plaques throughout the brain. Proteins known as chemokines regulate inflammation and the immune response. In both patients with AD and mouse AD models, the chemokine CXCL10 is found in high concentrations in the brain and may contribute to AD.

A new study in the Journal of Clinical Investigation indicates that activation of the CXCL10 receptor, CXCR3, contributes to AD pathology. Using a murine model of AD, Michael Heneka and colleagues at the University of Bonn found that mice lacking CXCR3 had reduced β-amyloid plaque formation. Importantly, loss of CXCR3 signaling in AD mice attenuated .

The results of this study suggest that CXCR3 should be explored as a potential therapeutic target for AD.


Explore further

Inflammatory mediator enhances plaque formation in Alzheimer's disease

More information: CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model, J Clin Invest. DOI: 10.1172/JCI66771
Citation: Targeting inflammatory pathway reduces Alzheimer's disease in mice (2014, December 15) retrieved 24 April 2019 from https://medicalxpress.com/news/2014-12-inflammatory-pathway-alzheimer-disease-mice.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more